

Qianbin Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9346620/publications.pdf>

Version: 2024-02-01

29
papers

423
citations

932766

10
h-index

752256

20
g-index

29
all docs

29
docs citations

29
times ranked

678
citing authors

#	ARTICLE	IF	CITATIONS
1	An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition. <i>Drug Discovery Today</i> , 2022, 27, 1457-1463.	3.2	9
2	Novel pyrazolo[3,4- <i>b</i>]pyridine derivatives: Synthesis, structure-activity relationship studies, and regulation of the AMPK/70S6K pathway. <i>Archiv Der Pharmazie</i> , 2022, , e2100465.	2.1	0
3	TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats. <i>Vascular Pharmacology</i> , 2022, 145, 107017.	1.0	3
4	Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-containing pyrazolo[3,4- <i>b</i>]pyridinones as a new series of AMPK α 1 activators. <i>Archiv Der Pharmazie</i> , 2021, 354, 21 e2000458.	2.1	6
5	Interdomain interactions dictate the function of the <i>Candida albicans</i> Hsp110 protein Msi3. <i>Journal of Biological Chemistry</i> , 2021, 297, 101082.	1.6	7
6	Novel Pyrazolo[3,4- <i>b</i>] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 691405.	1.6	2
7	Multistep virtual screening based identification of homeodomain-interacting protein kinase 2 inhibitors: An opportunity for treating Chronic Kidney Disease. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2021, 219, 104440.	1.8	1
8	New Insights Into Heat Shock Protein 90 in the Pathogenesis of Pulmonary Arterial Hypertension. <i>Frontiers in Physiology</i> , 2020, 11, 1081.	1.3	3
9	Discovery of Novel Pyrazolo[3,4- <i>b</i>] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11215-11234.	2.9	23
10	Targeted degradation of CD147 proteins in melanoma. <i>Bioorganic Chemistry</i> , 2020, 105, 104453.	2.0	10
11	Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115404.	1.4	7
12	Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4685-4700.	2.9	19
13	A novel dual MEK/PDK1 inhibitor 9za retards the cell cycle at G ₀ /G ₁ phase and induces mitochondrial apoptosis in non-small cell lung cancer cells. <i>PeerJ</i> , 2020, 8, e9981.	0.9	2
14	The Protective Effect of Fluorofenidone against Cyclosporine A-Induced Nephrotoxicity. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 656-668.	0.9	12
15	Synthesis and structure-activity relationships of pyrazolo[3,4- <i>b</i>]pyridine derivatives as adenosine 5'-monophosphate-activated protein kinase activators. <i>Archiv Der Pharmazie</i> , 2019, 352, e1900066.	2.1	8
16	Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 944-954.	1.4	15
17	Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1871-1881.	1.4	17
18	Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019, 19, 1544-1557.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 222-229.	1.0	5
20	Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives. <i>Medicinal Chemistry Research</i> , 2018, 27, 161-170.	1.1	7
21	Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases. <i>Current Medicinal Chemistry</i> , 2017, 24, 3203-3215.	1.2	5
22	Synthesis, preliminary biological evaluation and 3D-QSAR study of novel 1,5-disubstituted-2(1H)-pyridone derivatives as potential anti-lung cancer agents. <i>Arabian Journal of Chemistry</i> , 2016, 9, 721-735.	2.3	9
23	One-Pot-Synthesis of 1-Phenyl-1H-benzimidazole Derivatives Facilitated by Fe. <i>Chinese Journal of Organic Chemistry</i> , 2016, 36, 1672.	0.6	1
24	The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. <i>Future Medicinal Chemistry</i> , 2015, 7, 269-289.	1.1	60
25	Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. <i>Drug Discovery Today</i> , 2015, 20, 332-346.	3.2	74
26	Design, Synthesis and Anti-fibrosis Activity Study of N1-Substituted Phenylhydroquinolinone Derivatives. <i>Molecules</i> , 2012, 17, 1373-1387.	1.7	11
27	Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 850-853.	1.0	7
28	Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4526-4530.	1.0	36
29	Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1/2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6042-6046.	1.0	39